Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Japan Safety Panels Recognize 1st Death Tied to COVID Vaccine
Japan has so far reported roughly 2,000 deaths following COVID-19 vaccinations under its vaccine safety surveillance system. On March 10, health ministry safety panels determined that a causal link with a COVID-19 vaccine is “reasonably possible” for one of these…
To read the full story
Related Article
- Japan Safety Panels Recognize 2nd Death Possibly Linked to COVID Vaccine
July 31, 2023
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
January 23, 2023
- Still No Serious Safety Concerns with COVID-19 Vaccines: MHLW Panels
December 20, 2022
- 2 Women Die after BA.5 COVID Booster Shots: MHLW
November 14, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: Experts
October 11, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
September 5, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
August 8, 2022
REGULATORY
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…